ClinicalTrials.gov record
Terminated Phase 1 Interventional

Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection

ClinicalTrials.gov ID: NCT02109224

Public ClinicalTrials.gov record NCT02109224. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 16, 2026, 6:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase I and Pharmacokinetic Study of Ibrutinib in HIV-Infected Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Multiple Myeloma

Study identification

NCT ID
NCT02109224
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 1
Lead sponsor
National Cancer Institute (NCI)
NIH
Enrollment
72 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 31, 2014
Primary completion
Jun 30, 2015
Completion
Jun 30, 2015
Last update posted
Aug 19, 2015

2014 – 2015

United States locations

U.S. sites
7
U.S. states
4
U.S. cities
5
Facility City State ZIP Site status
UCLA Center for Clinical AIDS Research and Education Los Angeles California 90035
Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore Maryland 21287
Siteman Cancer Center at Washington University St Louis Missouri 63110
Memorial Sloan-Kettering Cancer Center New York New York 10065
Albert Einstein College of Medicine The Bronx New York 10461
Montefiore Medical Center-Einstein Campus The Bronx New York 10461
Montefiore Medical Center - Moses Campus The Bronx New York 10467-2490

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02109224, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 19, 2015 · Synced May 16, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02109224 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →